检索结果-南通市图书馆

Microbiota transplantation： concept, methodology and strategy for its modernization

在线全文

学校读者我要写书评

暂无评论

Protein & Cell 2018年第5期9卷 462-473页

作者： Faming Zhang Bota Cui Xingxiang He Yuqiang Nie kaichun wu Daiming Fan Medical Center for Digestive Diseases The Second Affiliated Hospital of Nanjing Medical University Nanjing 210011 China Key Lab of Holistic Integrative Enterology Nanjing Medical University Nanjing 211166 China Division of Microbiotherapy Sir Run Run Shaw Hospital Nanjing Medical University Nanjing 211166 China Department of Gastroenterology The First Affiliated Hospital of Guangdong Pharmaceutical University Guangzhou 510080 China Department of Gastroenterology Guangzhou Digestive Disease Center Guangzhou First People's Hospital Guangzhou Medical University Guangzhou 510180 China State Key Laboratory of Cancer Biology & Xijing Hospital of Digestive Diseases Fourth Military Medical University Xi'an 710032 China National Clinical Research Center for Digestive Diseases Xi'an 710032 China

Fecal microbiota transplantation （FMT） has become a research focus of biomedicine and clinical medicine in recent years. The clinical response from FMT for different diseases provided evidence for microbiota-host interactions associated with various disorders, including Clostridium difficile infection, inflammatory bowel disease, diabetes mellitus, cancer, liver cirrhosis, gut- brain disease and others. To discuss the experiences of using microbes to treat human diseases from ancient China to current era should be important in moving standardized FMT forward and achieving a better future. Here, we review the changing concept of microbiota transplantation from FMT to selective microbiota transplantation, methodology development of FMT and step- up FMT strategy based on literature and state experts＇ perspectives.

关键词： selective microbiota transplantation microbiome bacteria Clostridium difficile inflammatorybowel disease step-up fecal microbiota transplantationperspectives

USP33, a new player in lung cancer, mediates Slit-Robo signaling

在线全文

学校读者我要写书评

暂无评论

Protein & Cell 2014年第9期5卷 704-713页

作者： Pushuai Wen Ruirui Kong Jianghong Liu Li Zhu Xiaoping Chen Xiaofei Li Yongzhan Nie kaichun wu Jane Y. wu State Key Laboratory of Brain and Cognitive Science Institute of Biophysics Chinese Academy of Sciences Beijing 100101 China Department of Neurology Center for Genetic Medicine Lurie Cancer Center Northwestern University Feinberg School of Medicine 303 E. Chicago Ave. Chicago IL 60611 USA Department of Thoracic Surgery Tangdu Hospital Fourth Military Medical University Xi'an 710038 China State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases Fourth Military Medical University Xi'an 710032 China University of Chinese Academy of Sciences Beijing 100049 China Department of Pathophysiology Liaoning Medical University Jinzhou 121001 China

Ubiquitin specific protease 33 （USP33） is a multifunctional protein regulating diverse cellular processes. The expression and role of USP33 in lung cancer remain unexplored. In this study, we show that USP33 is down-regulated in multi- ple cohorts of lung cancer patients and that low expression of USP33 is associated with poor prognosis. USP33 medi- ates Slit-Robo signaling in lung cancer cell migration. Downregulation of USP33 reduces the protein stability of Robol in lung cancer cells, providing a previously unknown mechanism for USP33 function in mediating Slit activity in lung cancer ceils. Taken together, USP33 is a new player in lung cancer that regulates Slit-Robo signaling. Our data suggest that USP33 may be a candidate tumor suppressor for lung cancer with potential as a prognostic marker.

关键词： USP33 Slit Robo lung cancer Slit-Robosignaling tumor suppressor prognostic marker

Research highlights of clinical oncology early 2022

在线全文

学校读者我要写书评

暂无评论

Holistic Integrative Oncology 2022年第1期1卷 71-75页

作者： kaichun wu Xijing Hospital of Digestive Diseases Fourth Military Medical UniversityXi’anChina

Advance in clinical oncology is highly relied on development of cancer research and clinical *** has been ample evidence regarding the new therapeutic drugs,agents or techniques for the treatment of *** did a broad literature search to catch the latest progress in the cancer *** is a brief review of the newly released results of clinical trials including surgical modalities,immune checkpoint blockade,chimeric antigen receptor T-cell(CAR T)therapy,antibody-drug conjugates and tumor vaccines,*** or patient assessment of cancer therapy were also discussed.

关键词： Cancer Drug therapy Immunotherapy Antibody Vaccine Biomarker

Time-adjusted average Mayo endoscopic score predicts the risk of disease extent progression in distal ulcerative colitis patients

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Gastroenterology Report 2022年第1期10卷 349-355页

作者： Jian Wan Xuan Wang Yujie Zhang Xianmin Xue Hui Jia Min Wang Jie Liang kaichun wu State Key Laboratory of Cancer Biology National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive DiseasesFourth Military Medical UniversityXi’anShaanxiP.R.China Department of Neurology Xijing HospitalFourth Military Medical UniversityXi’anShaanxiP.R.China Department of Histology and Embryology School of Basic MedicineXi’an Medical UniversityXi’anShaanxiP.R.China

Background:Ulcerative colitis(UC)is a chronic lifelong *** disease extent of UC can progress over *** study aimed to assess whether cumulative inflammatory burden(CIB)is associated with disease extension in distal UC(proctitis[E1]and left-sided colitis[E2])patients,and to develop a quantified indicator of ***:In this retrospective study based on a prospective registry,distal UC patients receiving colonoscopies in Xijing Hospital(Xi’an,China)fromJanuary 2000 to May 2019 were *** developed a new score,namely the time-adjusted average Mayo endoscopic score(TA-MES),calculated as dividing the sum of the cumulative averageMES over a period of surveillance time by the length of the endoscopic examination interval,to quantify the *** regression was used to identify other potential risk ***:A total of 295 UC patients were followed for 1,487.02 *** them,140 patients(47.5%)experienced disease *** analysis showed that the TA-MES was significantly associated with disease extension in E1(hazard ratio[HR],2.90;95%confidence interval[CI],1.58–5.33,P=0.001)and E2(HR,1.89;95%CI,1.16–3.09,P=0.011)*** risk factors included hemoglobin of<90 g/L and appendiceal skip inflammation;the protective factors included age,E2 at diagnosis,former smoking,and 5-aminosalicylic acid ***,MES at diagnosis,maximal MES,and mean MES failed to estimate the risk of disease ***:TA-MES is a good quantified indicator of CIB and is independently associated with increased disease extension in distal UC *** the dynamic multiple scoring system could be used as a risk factor in other chronic relapsing–remitting diseases is a direction for future research.

关键词： Mayo endoscopic score disease extension ulcerative colitis distal

Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis:a 2-year follow-up study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Frontiers of Medicine 2013年第2期7卷 255-263页

作者： Jiangyi Zhu Yongquan Shi Xinmin Zhou Zengshan Li Xiaofeng Huang Zheyi Han Jianhong Wang Ruian Wang Jie Ding kaichun wu Ying Han Daiming Fan State Key Laboratory of Cancer Biology Institute of Digestive DiseasesXijing HospitalFourth Military Medical UniversityXi’an 710032China Department of Pathology Xijing HospitalFourth Military Medical UniversityXi’an 710032China

The efficacy of ursodeoxycholic acid(UDCA)on long-term outcome of primary biliary cirrhosis(PBC)has been less documented in Chinese *** aimed to assess the therapeutic effect of UDCA on Chinese patients with *** the present study,67 patients with PBC were treated with UDCA(13–15 mg∙kg^(-1)∙day^(-1))and followed up for 2 years to evaluate the changes of symptoms,laboratory values and histological *** the results indicated,fatigue and pruritus were obviously improved by UDCA,particularly in patients with mild or moderate *** alkaline phosphatase andγ-glutamyl transpetidase levels significantly declined at year 2 comparing to baseline values,with the most profound effects achieved in patients at stage *** levels of alanine aminotransferase and aspartate aminotransferase significantly decreased whereas serum bilirubin and immunoglobulin M levels exhibited no significant *** feature was stable in patients at stages 1–2 but still progressed in patients at stages 3–*** biochemical response of patients at stage 2 was much better than that of patients at stages 3–*** data suggest that,when treated in earlier stage,patients in long-term administration of UDCA can gain favorable results not only on symptoms and biochemical responses but also on *** is also indicated that later histological stage,bad biochemical response and severe symptom may be indicators of poor prognosis for UDCA therapy.

关键词： primary biliary cirrhosis ursodeoxycholic acid Chinese biochemical response therapeutic efficacy

Association of miR-483,miR-214 and miR-210 with prognosis of esophageal squamous cell cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Association of miR-483,miR-214 and miR-210 with prognosis of...

2012中国消化系疾病学术大会

作者： Liu Hong kaichun wu Daiming Fan Xijing Hospital of Digestive Diseases Fourth Military Medical University

In this study,we have firstly investigated the relation of miR-483,miR-214 and miR-210 with the prognosis of patients with esophageal squamous cell *** expression of miR-483,214 and 210 was detected in 25 eases of esophageal cancer tissues and matched adjacent benign esophageal tissues by quantitative real-time PCR. The expression of miR-483 and miR-214 was found significantly up-regulated in esophageal squamous cell cancer

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

胃癌疫苗的研究现状

中国实用内科杂志 2006年第24期26卷 1917-1920页

作者：吴开春陈瑜第四军医大学附属西京医院消化内科肿瘤生物学国家重点实验室

1简介胃癌是世界上第二常见的癌症。近50年来,虽然在全球范围内,特别是部分发达国家中,胃癌的发病率和病死率呈下降趋势,但每年仍有约100万新发病例。由于缺乏早期诊断的手段,大部分有症状的胃癌患者在确诊时已属晚期。目前传统的治疗... 详细信息

1简介胃癌是世界上第二常见的癌症。近50年来,虽然在全球范围内,特别是部分发达国家中,胃癌的发病率和病死率呈下降趋势,但每年仍有约100万新发病例。由于缺乏早期诊断的手段,大部分有症状的胃癌患者在确诊时已属晚期。目前传统的治疗方法为手术、化疗、放疗,这些治疗为侵入性或毒副反应明显,且均不能有效解决肿瘤转移、复发等问题。化疗后常发生多药耐药现象。总之,[第一段]

关键词：胃癌患者细胞表位 CTL Ag 多表位疫苗免疫表位疫苗胃癌相关抗原抗原表位模拟表位碳水化合物抗原

Routine clinical administration of 4-week alverine citrate and simeticone combination relief global IBS symptoms

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Open Journal of Gastroenterology 2014年第1期4卷 32-39页

作者： Xiangping Wang Yikuan Feng Jiansheng Li Zibin Tian Dong Wei Lingzhi Qi Lifeng Fang kaichun wu Gastroenterology Institute 1st Affiliated Hospital of Zhengzhou University Zhengzhou China Gastroenterology Institute No. 150 Central Hospital of PLA Luoyang China Gastroenterology Institute The Affiliated Hospital of Medical College Qingdao University Qingdao China Gastroenterology Institute The People’s Hospital of Jilin Province Changchun China Gastroenterology Institute Weifang People’s Hospital Weifang China Gastroenterology Institute Zhengzhou First People’s Hospital Zhengzhou China State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases Fourth Military Medical University Xi’an China

Introduction: The primary treatment aim for irritable bowel syndrome (IBS) is to relieve overall symptoms which can significantly impair the patient’s quality of life (QOL);however, it generally requires a high pill burden that may be improved by administration of combinatorial formulations. Thus, the effectiveness of alverine citrate and simeticone combination (ACS) for global symptom relief for IBS was investigated in this non-interventional study. Patients and Methods: ROME III IBS patients (n = 640;52.3% male: mean age: 43.6 ± 12.5 years) with abdominal pain and discomfort ≥60 of 0-100 visual analogue scale (VAS) were included in a prospective, multicenter, non-interventional study at 26 Chinese sites from December 2010 to January 2012. Patients received alverine citrate (60 mg) with simeticone (300 mg) (ACS) 3× daily for 4 weeks. Pain/discomfort and bloating/distension were assessed by VAS. Global symptoms and QOL were assessed by 7-point and 5-point Likert scales, respectively. Post-treatment bowel function was assessed by Bristol Stool Form Scale (BSFS) and treatment-related adverse events (AEs) were recorded. Results: Of 640 patients, 540 (84.4%) completed the study, and 100 (15.6%) withdrew. In total, 87.5% reported bloating at baseline. After 4-week ACS treatment, 89.1% reported global symptom improvement. Furthermore, 4-week ACS treatment reduced pain and bloated VAS scores significantly from 78.4 ± 9.9 to 32.1 ± 21.0 and from 63.2 ± 27.2 to 22.6 ± 20.9, respectively (both p < 0.001), decreased diarrhea or constipation occurrence from 67.2% to 10.2% (p < 0.001), and reduced IBS impact on QOL with only 2 treatment-related AEs. Conclusion: Routine clinical administration of ACS for IBS over a 4-week period provides effective relief of IBS symptoms and improves QOL in IBS patients.

关键词： Alverine Citrate Abdominal Pain Bloating Irritable Bowel Syndrome Simeticone

中国炎症性肠病相关结直肠癌的风险评估和监测

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华消化杂志 2016年第7期36卷 441-443页

作者：吴开春张琴第四军医大学西京消化病医院消化科西安710032

IBD 指一组病因未明的肠道慢性炎性反应性疾病，包括 UC 和 CD。IBD 患者肠道反复发生慢性炎性反应，易出现多种合并症，炎症相关性结直肠癌（colitis-associated colorectal cancer，CAC）是长程IBD 患者最严重的并发症。有效监测和化... 详细信息

IBD 指一组病因未明的肠道慢性炎性反应性疾病，包括 UC 和 CD。IBD 患者肠道反复发生慢性炎性反应，易出现多种合并症，炎症相关性结直肠癌（colitis-associated colorectal cancer，CAC）是长程IBD 患者最严重的并发症。有效监测和化学预防是防治 IBD 癌变的重要手段。

关键词：炎症性肠病结直肠癌风险评估监测中国慢性炎性 IBD 应性疾病